Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 January 2020, 18:11 HKT/SGT
Share:
TOT BIOPHARM Biological Drug R&D Project Makes List of National Major Scientific and Technological Special Projects for "Significant New Drug Development"
Receives Central Government Funding

HONG KONG, Jan 2, 2020 - (ACN Newswire) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK) is pleased to announce that the Company has received notice of Project Topics of 2019 Implementation Plan of Major Special Technology Projects for "Significant New Drug Creation" (Hygiene and Technology Project Document No. (2019)764) from the Development Center for Medical Science & Technology ("DCMST") under the National Health Commission, giving approval to its application for "clinical research and industrialization of category 1 biological drug 'monoclonal antibody anti-VEGF' (item no.: TAB014) for treating wet macular degeneration", and the project has been included among the National Major Scientific and Technological Special Projects for "Significant New Drug Development", reflective of national endorsement, thus will receive central government funding.

Major Scientific and Technological Special Projects for "Significant New Drug Development" is among the 16 special projects in the National Outlines for Medium and Long-term Planning for Scientific and Technological Development (2006-2020). Those projects are of utmost importance to the technological development of China as they involve technological breakthroughs and use of integrated resources to complete within certain timeframes major strategic products, critical generic technologies and major engineering efforts, to help the nation realize her goals. The 16 major special projects included significant new drug development, large aircrafts, manned space and lunar exploration projects.

TOT BIOPHARM places great emphasis on technological innovation and has actively increased investment in the R&D in recent years. The Company's new drug - TAB014 monoclonal antibody products - R&D project making it on the list of national major science and technology projects is not only proof of the country's recognition for the Company's technological innovation and related products, but is also conducive to speeding up the development and commercialization of the drug to more quickly benefit patients.

The Company's drug candidate anti-VEGF monoclonal antibodies (project code: TAB014) for treating wet macular degeneration is a kind of bevacizumab based eye injection product for addressing retinal neovascularization. The project is progressing well and is currently in Phase I clinical research. The Company expects to complete Phase III clinical research for TAB014 before 2022, with the product launch to follow in 2023.




Jan 2, 2020 18:11 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Washington Companies Refuses Safety Recommendations  
July 10, 2020 19:20 HKT/SGT
TOYOTA GAZOO Racing WRC Challenge Program  
July 10, 2020 16:22 HKT/SGT
Komnas HAM Papua presents the case of victim MB's civilian death in Asiki  
July 10, 2020 16:00 HKT/SGT
HK Main-Board Listed Tianda Pharmaceuticals(00455.HK) , A Promising Outlook for Growth  
July 10, 2020 15:26 HKT/SGT
Hitachi ABB Power Grids India Wins INR 120 Crore Order for Indian Railways Electrification  
July 10, 2020 08:07 HKT/SGT
Lifequest World (LQWC) subsidiary Biopipe Global enters US Market with Shipment of its Revolutionary Sludge-Free Biological Wastewater Treatment Plant to California  
July 10, 2020 06:00 HKT/SGT
Sri Trang Gloves PCL (SET: STGT) debuts on Stock Exchange of Thailand  
July 9, 2020 16:00 HKT/SGT
AVIA ends its first online conference 'the OTT Virtual Summit' on a high note  
July 9, 2020 15:00 HKT/SGT
NEC Solution Innovators Establishes "FonesLife," a healthcare business company that contributes to extending healthy life expectancy  
July 9, 2020 13:34 HKT/SGT
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease  
July 9, 2020 11:20 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: